Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.

@article{Balsas2012BortezomibRI,
  title={Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.},
  author={Patricia Balsas and Patricia Gal{\'a}n-Malo and Isabel Marzo and J. M. Goldspiel U. S. Naval},
  journal={Leukemia research},
  year={2012},
  volume={36 2},
  pages={212-8}
}
Bortezomib is a proteasome inhibitor important to the therapy of multiple myeloma (MM), though a number of patients show resistance to this drug. To study the cellular basis of this resistance we have generated a MM cell line displaying enhanced (5-6-fold) resistance to bortezomib by serial cultivation of RPMI 8226 cells with increasing concentrations of this drug. Bortezomib-resistant cells (8226/7B) became bigger in size than parental cells and nearly doubled the amount of DNA per cell… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Resistance to Proteasome Inhibitors in Cancer

Resistance to Targeted Anti-Cancer Therapeutics • 2014
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…